Clinical trial
Evaluation of the Efficacy and Safety of a Short-course, Daily, 4-month Regimen Including Isoniazid, Pyrazinamide, Rifapentine and Moxifloxacin (2HZPM/2HPM) for the Treatment of Drug-susceptible Pulmonary Tuberculosis in Taiwan (ESCAPE-TB)
NCT04856644 is registered in ClinicalTrials.gov with Kaohsiung Veterans General Hospital. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of the Efficacy and Safety of a Short-course, Daily, 4-month Regimen Including Isoniazid, Pyrazinamide, Rifapentine and Moxifloxacin (2HZPM/2HPM) for the Treatment of Drug-susceptible Pulmonary Tuberculosis in Taiwan (ESCAPE-TB)
- Lead sponsor
- Kaohsiung Veterans General Hospital.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- January 1, 2020
- Completion date
- December 31, 2024
- Enrollment
- 333 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.